Compare AbbVie Inc (ABBV) vs Lemonade Inc (LMND) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Lemonade (LMND) trades at $77.59, up 8.49% in the last session, showing strong momentum with a bullish technical outlook. The stock has consistently beaten earnings expectations in recent quarters, with revenue growth accelerating from $257M in 2022 to $738M in 2025. However, the company remains unprofitable with a -16.44% net income margin, though losses are narrowing. Recent expansion into new states and reinsurance program improvements provide positive catalysts.

While LMND shows promising growth and technical strength, the stock trades above the $71.75 analyst consensus target. The path to profitability remains the key challenge, with negative cash flow from operations and high valuation multiples creating risk. Investors face a trade-off between strong revenue growth and persistent losses in a competitive insurance market.